高迁移率族蛋白1参与系统性红斑狼疮发病机制的研究进展

Research Progress of High Mobility Group Box 1 in Pathogenesis of Systemic Lupus Erythematosus

系统性红斑狼疮(SLE)是一种累及多系统、多脏器的高异质性自身免疫性疾病,其细胞和分子机制目前仍不十分明确。高迁移率族蛋白1(HMGB1)是一种主要存在于真核细胞核内的非组蛋白,释放至细胞外的HMGB1可作为损伤相关分子模式促进免疫紊乱和炎症反应。SLE患者循环和受累组织中HMGB1胞外释放增加,而HMGB1可作用于单核巨噬细胞、中性粒细胞、树突状细胞及淋巴细胞等免疫细胞,亦可作用于肾脏、神经系统等受累组织中的局部细胞参与SLE发病,可能是SLE的潜在治疗靶点,但靶向HMGB1治疗SLE的方法和有效性仍有待进一步探索。

Systemic lupus erythematosus(SLE)is a highly heterogeneous autoimmune disease involving multiple systems and organs.Its cellular and molecular mechanisms are still unclear.High mobility group box 1(HMGB1)is a non-histone protein that mainly exists in the nucleus of eukaryotic cells.The release of HMGB1 outside the cell can be used as a damage-related molecular model to promote immune disorders and inflammatory response.The extracellular release of HMGB1 in circulating and involved tissues of SLE patients increases,and HMGB1 can act on immune cells such as monocyte macrophages,neutrophils,dendritic cells and lymphocytes,as well as local cells in affected tissues such as kidney and nervous system,which may be a potential therapeutic target for SLE.However,the method and effectiveness of targeted HMGB1 in the treatment of SLE still need to be further explored.